Loading…
← CockpitCompetitor Analysis › 688363.SS Bloomage Biotechnology Corp. Ltd. Class AOpen in the cockpit ↗

Bloomage Biotechnology Corp. Ltd. Class A688363.SSCompetitor analysis, valuation and peers

China · CNY·Materials›Chemicals: Specialty

World's largest producer of hyaluronic acid, supplying raw material and finished dermal-filler and skincare products for medical aesthetics and cosmetics.

≈ A raw-material supplier plus a skincare brand owner rolled into oneMomentum neutral 51
Mkt cap
$2.27B
US dollars, full cap
Free float
33%
of shares outstanding
$/day
$12.7M
20-day average traded
Fwd P/E
52.0×
forward earnings
ROIC−WACC
-2.8 pp
WACC 8.2%
Hurdle
+9 pp
Req g minus delivered
Next earnings
134 days
1 Apr 2027
Close · CNYCN¥31.55
1D-5.5%
1W-8.1%
1M-9.9%
3M-18.2%
6M-21.0%
YTD-27.8%
1Y-39.4%
ATR %3.1%
52w lowhigh40.1% off high

What Bloomage Biotechnology does

World's largest producer of hyaluronic acid, supplying raw material and finished dermal-filler and skincare products for medical aesthetics and cosmetics.

Began as an ingredient supplier selling hyaluronic acid by weight to cosmetic, drug and food makers, and has moved up the chain into its own skincare brands and injectable fillers, which capture more value per gram but cost more in marketing. Ingredient sales still follow volume and price of a commodity-like material.

In one line: A raw-material supplier plus a skincare brand owner rolled into one.

Products and services

  • Hyaluronic acid raw material
  • Injectable dermal fillers
  • Skincare/cosmetics brands

Customers

  • Pharma/cosmetics companies (raw material)
  • Aesthetic clinics
  • Consumers (branded skincare)

Where it sits in the supply chain

  • Health Care
  • Biotechnology
  • Hyaluronic acid & aesthetics

What could go right

  • Global HA raw-material demand
  • Consumer skincare brand growth

What could go wrong

  • Consumer skincare brand competition/marketing spend
  • HA raw-material price competition

Moat: narrow (scale, process know-how, brand). World-leading fermentation-based HA production scale plus a growing portfolio of consumer skincare brands.

Headquarters: Jinan, China · Employees: 3,698

Named competitors

Bloomage Biotechnology at a glance

Size Bloomage Biotechnology (688363.SS) is a China Materials company (Chemicals: Specialty) with a market value of $2.27B, the 1063rd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥31.55 on 18 Nov 2026.

Performance Over six months the shares fell 21.0%, against -16.7% for the median peer and -20.0% for the China market (cap-weighted) — 9th lowest of 21 in its peer set.

Growth Revenue fell 21.5% over the last twelve months (peer median +10.8%); the operating margin is 4.6% (peer median 7.5%).

Valuation It trades at 52.0× forward earnings against a peer median of 16.1× (3rd most expensive of 17).

Price implies For today's price to make sense, revenue must grow about 19% a year for seven years (Req g). Recent delivered growth is +10%, so the hurdle is +9 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 2.8 points below its cost of capital (8.2% WACC).

Next results Next results expected around 1 Apr 2027 (exchange calendar; dates can move).

Relative performance

809010021 May 202621 Aug 202618 Nov 2026Peer median 83688363.SS 80
Six months, rebased to 100: Bloomage Biotechnology against the median of its 20 peers (local-currency closes).

Bloomage Biotechnology financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥3.63BCN¥4.17BCN¥5.31BCN¥6.01BCN¥6.28B
Revenue growth—-21%-12%-4%—
Gross profitCN¥2.58BCN¥2.72BCN¥3.77BCN¥4.28BCN¥4.75B
EBITDAn/aCN¥627MCN¥554MCN¥860MCN¥1.18B
Net incomeCN¥226MCN¥292MCN¥174MCN¥593MCN¥971M
Free cash flowCN¥532MCN¥312M-CN¥124M-CN¥317M-CN¥28.6M
Capital expenditureCN¥363MCN¥326MCN¥721MCN¥1.03BCN¥696M
Total debtCN¥489MCN¥353MCN¥360MCN¥215MCN¥421M

Quarterly statements and history in the cockpit →

Bloomage Biotechnology competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-20%-10%0%DEEPAKNTR6006233012863008214118ROG0117906050204202600339600500002145SDF300073688778603002GRWRHITECH688363.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Bloomage Biotechnology is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%20×40×60×DEEPAKNTR6006233012864118ROG60502042026003392768300073601568688778603002GRWRHITECH688363.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Bloomage Biotechnology is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%6006233012863008214118ROG4202KEMIRA600500688778GRWRHITECH688363.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Bloomage Biotechnology is the large dot.

Bloomage Biotechnology competitors and peer comparison

Head to head with its named competitors (688363.SS vs 300896.SZ vs GALD.SW vs ABBV)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Bloomage Biotechnology 688363.SS$2.27B-21%-22%5%52.0×19.0%
IMEIK Technology Development 300896.SZ$3.66B-25%-7%45%22.4×17.5%
Galderma GALD.SW$51.9B+18%+16%19%45.7×18.0%
AbbVie ABBV$506B+35%+11%36%18.1×-0.1%

How Bloomage Biotechnology compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Bloomage Biotechnology against its 20 peers (data as of 18 Nov 2026)
Measure688363.SSPeer medianRank in peer set
1-month return-9.9%-7.2%9th lowest of 21
6-month return-21.0%-16.7%9th lowest of 21
Distance from 52-week high-40.1%-39.7%11th highest of 21
Revenue growth (TTM)-21.5%+10.8%lowest of 21
Operating margin4.6%7.5%6th lowest of 20
Forward P/E52.0×16.1×3rd most expensive of 17
Growth the price implies (Req g, 7 yrs)19.0%10.8%3rd most demanding of 12
Growth delivered (Del g)+9.8%+8.0%4th highest of 12
Hurdle (Req g minus delivered)+9.2 pp+10.3 pp6th least demanding of 12
ROIC minus cost of capital-2.8 pp-1.3 pp6th lowest of 19

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Bloomage Biotechnology 688363.SSChina$2.27B-21%-22%5%52.0×19.0%+9.8%
Deepak Nitrite DEEPAKNTR.NSIndia$2.28B-13%+25%14%16.8×n/an/a
Shanghai Huayi 600623.SSChina$2.31B-16%+5%n/a13.6×-11.3%+10.3%
Sichuan Qiaoyuan Gas 301286.SZChina$2.33B-37%+8%26%59.2×27.6%+8.0%
Shandong Dongyue Silicone Material 300821.SZChina$2.19B-23%+13%13%n/a18.8%+8.6%
Kaneka 4118.TJapan$2.35B+17%+6%5%12.0×3.3%+7.0%
Rogers ROGUnited States$2.18B-8%+7%10%26.3×10.8%+0.2%
SKC 011790.KSSouth Korea$2.42B-52%+24%-9%n/an/an/a
Zhejiang Yonghe Refrigerant 605020.SSChina$2.12B-13%+25%18%13.2×n/an/a
Daicel 4202.TJapan$2.45B+31%+7%8%10.9×4.2%+8.1%
China Petroleum Engineering 600339.SSChina$2.46B-22%+8%1%24.5×n/an/a
Kemira KEMIRA.HEFinland$2.47B-12%-3%8%15.8×3.9%+2.6%
Sinochem International 600500.SSChina$2.06B-31%-5%-1%n/a11.0%-2.7%
Tinergy Chemical 002145.SZChina$2.06B-20%+17%9%n/an/an/a
K+s SDF.DEGermany$2.51B-13%+7%28%10.5×n/an/a
Qingdao Gon Technology 2768.HKHong Kong$2.52B-17%+20%7%9.7×n/an/a
Beijing Easpring Material Technology 300073.SZChina$2.56B-45%+116%5%17.8×n/an/a
Shaanxi Beiyuan Chemical Industry 601568.SSChina$1.99B-13%-8%-4%11.1×10.5%-1.8%
XTC New Energy Materials (Xiamen) 688778.SSChina$2.59B-51%+78%4%16.5×13.7%+20.0%
Epoxy Base Electronic Material 603002.SSChina$1.98B-22%+73%7%64.6×n/an/a
Garware Hi-Tech Films GRWRHITECH.NSIndia$1.95B+42%+15%21%38.7×39.5%+16.6%

Questions

Who are Bloomage Biotechnology's main competitors?
Named competitors: IMEIK Technology Development (300896.SZ), Galderma Group (GALD.SW), AbbVie (Allergan Aesthetics) (ABBV). The cockpit's measured peer set (industry) also includes Deepak Nitrite (DEEPAKNTR.NS), Shanghai Huayi (600623.SS), Sichuan Qiaoyuan Gas (301286.SZ), Shandong Dongyue Silicone Material (300821.SZ), Kaneka (4118.T), Rogers (ROG).
Is Bloomage Biotechnology expensive compared with its peers?
On forward p/e it trades at 52.0× against a peer median of 16.1×, 3rd most expensive of 17 in its peer set. For today's price to make sense, revenue must grow about 19% a year for seven years (Req g). Recent delivered growth is +10%, so the hurdle is +9 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Bloomage Biotechnology stock performed?
Over six months to 18 Nov 2026 the shares returned -21.0% against -16.7% for the median peer; over one year -39.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.